The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial: study protocol for a randomized clinical multicenter trial

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Jenmalm Maria C) > The effect of tinza...

The effect of tinzaparin on biomarkers in FIGO stages III-IV ovarian cancer patients undergoing neoadjuvant chemotherapy - the TABANETOC trial : study protocol for a randomized clinical multicenter trial

Karlsson, Anna (författare): Department of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Lindahl, Gabriel (författare): Department of Oncology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Spetz Holm, Anna-Clara (författare): Department of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

visa fler...

Bergmark, Karin (författare): Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Dahm Kähler, Pernilla (författare): Department of Obstetrics and Gynecology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden

Fekete, Boglarka (författare): Department of Oncology, Sahlgrenska University Hospital, Gothenburg, Sweden

Ottander, Ulrika (författare): Umeå universitet,Obstetrik och gynekologi

Öfverman, Charlotte, 1970- (författare): Umeå universitet,Institutionen för diagnostik och intervention,Onkologi

Israelsson, Pernilla (författare): Umeå universitet,Institutionen för diagnostik och intervention,Onkologi

Falknäs, Laila (författare): Department of Obstetrics and Gynecology, Ryhov hospital, Sweden

Rosenmüller, Anders (författare): Department of Obstetrics and Gynecology, Västervik hospital, Sweden

Tiefenthal Thrane, Malena (författare): Department of Obstetrics and Gynecology, Sweden

Halili, Shefqet (författare): Department of Obstetrics and Gynecology, Värnamo hospital, Sweden

Lindahl, Tomas L. (författare): Department of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology, Linköping University, Linköping, Sweden

Jenmalm, Maria C. (författare): Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

Kjølhede, Preben (författare): Department of Obstetrics and Gynecology, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden

visa färre...

(creator_code:org_t)

Medical Journals Sweden, 2024
2024
Engelska.
Ingår i: Acta Oncologica. - : Medical Journals Sweden. - 0284-186X .- 1651-226X. ; 63, s. 581-585

Relaterad länk:: https://doi.org/10.2...; visa fler...; https://umu.diva-por... (primary) (Raw object); https://urn.kb.se/re...; https://doi.org/10.2...; visa färre...

Tidskriftsartikel (refereegranskat)

Abstract Ämnesord

Stäng

Background: Tinzaparin, a low-molecular weight heparin (LMWH), has shown anti-neoplastic properties in animal models and in in vitro studies of human cancer cell lines. The reduction of CA-125 levels during neoadjuvant chemotherapy (NACT) in patients with epithelial ovarian cancer (EOC) co-varies with the prognosis; the larger the decrease in CA-125, the better the prognosis.Purpose: This study aims to evaluate the potential anti-neoplastic effects of tinzaparin by investigating changes in serum CA-125 levels in advanced EOC patients who receive NACT.Material and methods: This is an open randomized multicenter pilot trial. Forty patients with EOC selected to receive NACT will be randomized 1:1 to receive daily addition of tinzaparin or no tinzaparin. The processing and treatment of the patients will otherwise follow the recommendations in the Swedish National Guidelines for Ovarian Cancer. Before every cycle of chemotherapy, preoperatively, and 3 weeks after the last cycle of chemotherapy, a panel of biomarkers, including CA-125, will be measured.Patients: Inclusion criteria are women aged 18 years or older, World Health Organization performance status 0–1, histologically confirmed high-grade serous, endometrioid or clear cell EOC, International Federation of Gynecology and Obstetrics (FIGO) stages III-IV. In addition, a CA-125 level of ≥ 250 kIE/L at diagnosis. Exclusion criteria are contraindications to LMWH, ongoing or recent treatment with unfractionated heparin, LMWH, warfarin or non-vitamin K antagonist oral anticoagulants.Interpretation: This study will make an important contribution to the knowledge of the anti-neoplastic effects of tinzaparin in EOC patients and may thus guide the planning of a future study on the impact of tinzaparin on survival in EOC.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Acta Oncologica (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Karlsson, Anna; Lindahl, Gabriel; Spetz Holm, Anna ...; Bergmark, Karin; Dahm Kähler, Per ...; Fekete, Boglarka; visa fler...; Ottander, Ulrika; Öfverman, Charlo ...; Israelsson, Pern ...; Falknäs, Laila; Rosenmüller, And ...; Tiefenthal Thran ...; Halili, Shefqet; Lindahl, Tomas L ...; Jenmalm, Maria C ...; Kjølhede, Preben; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Cancer och onkol ...

Artiklar i publikationen: Acta Oncologica

Av lärosätet: Umeå universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se